Articles
Consultation on cost recovery for gene technology regulator
The Department of Health and Ageing (DoHA) is undertaking an assessment and development of a cost recovery model for services provided by the Office of the Gene Technology Regulator (OGTR). DoHA has engaged PricewaterhouseCoopers (PwC) to undertake an economic analysis of the gene technology sector, and PwC is seeking input from sector stakeholders through the stakeholder survey. [ + ]
Mimicking a cure
A collaboration of Melbourne scientists who describe themselves as a “happy confluence” is shedding much-needed light on how the body controls nervous system myelination, and how their tiny peptide ‘mimic’ could help patients with neurodegenerative disease. [ + ]
CSL boosts FY13 profit by 19%
CSL (ASX:CSL) recorded 19% higher profit for FY13 as well as 7% higher revenue, and has announced the appointment of a new director. [ + ]
One chemical - two crystal colours
A surprise for chemists studying agostic bonds was the development of crystals of two different colours from one chemical in one flask. [ + ]
AmpliPhi presents CF lung data at phage summit
AmpliPhi BioSciences has used the Evergreen International Phage Meeting to present data supporting the effectiveness of bacteriophage treatments in P. aeruginosa infections. [ + ]
Six tips for selecting a laboratory workstation
Buying technician workstations for your laboratory is a major capital expense, deserving of careful consideration to avoid making a costly mistake. Follow these six tips for selecting a laboratory workstation that meets all your current needs, while positioning you to adapt to whatever comes down the parkway. [ + ]
Patrys myeloma trial to move to final group
Patrys (ASX:PAB) has received safety board approval to move to the final group in its multidose escalation study of PAT-SM6 in multiple myeloma. [ + ]
DNA - a silent witness
Forensic science is about to be transformed with the use of new technology to predict a person’s physical appearance - a molecular photofit derived from DNA found at a crime scene. [ + ]
Cost-effectively convert a conventional microscope into a billion-pixel imaging system
Usually microscopists have to decide between high resolution and a small field of view or low resolution and a large field of view. But that need no longer be the case. [ + ]
Engaging the unengaged in science? Try a little harder
The strange but true fact is: not everybody is absolutely fascinated by science, nor thinks it is vital. [ + ]
You are what you earn: chemical body burden reflects socioeconomic status
Using data from the US National Health and Nutrition Examination Survey, a research team analysed possible links between a person’s socioeconomic status and the prevalence of chemicals in their body. [ + ]
Five frequently asked questions about temperature and humidity validation/mapping
The US Food and Drug Administration’s (FDA) regulations tell us that we must identify the environmental conditions that can affect the strength, identity, safety, quality and purity of our regulated products, whether they are pharmaceuticals, medical devices or biologic products. The FDA regulations also say we must be able to demonstrate that we have maintained our product storage spaces such that the required storage conditions for our products have been met. [ + ]
Aussie biotechs must plan for weakened dollar
The Australian Life Sciences Index outperformed the All Ordinaries in Q4, and the weaker dollar presents both challenges and opportunities for the sector, according to the latest PwC report. [ + ]
Chronic inflammatory disease on trial
The results of clinical trial using cellular therapy in patients with Crohn’s disease were so encouraging the research was published before the trail had been completed. [ + ]
Bionomics signs up to US$172m deal with Merck
Bionomics (ASX:BNO) has entered a small molecule pain drug research and option agreement with pharmaceutical giant Merck that could be worth up to US$172m. [ + ]
